Inhibitors of spore germination act against diverse human fungal pathogens
- 1University of Wisconsin-Madison
Abstract
Current antifungal drugs often cause severe side effects due to the conservation of molecular targets between fungal and mammalian cells. One way to avoid host toxicity in future antifungals is to leverage molecules with targets involved in processes unique to fungi, such as spore germination. Germination is conserved in several of the most critical fungal pathogens but absent in mammalian cells. In this work we evaluated 191 small molecule inhibitors of Cryptococcus germination for their abilities to inhibit germination of another fungal pathogen, Aspergillus fumigatus, as well as yeast growth of Candida albicans and a pan-resistant isolate of Candida (Candidozyma) auris. The cytotoxicity of these inhibitors towards human hepatocytes and erythrocytes was also assessed. Overall, we identified 101 molecules that were either 1) germination-specific inhibitors in one or both germinating species tested, or 2) inhibitory to both germination and vegetative growth in one or more species tested. The majority of these molecules exhibited minimal toxicity to the human cell types tested. Molecules were scored and ranked for therapeutic potential based on assay data. For two key molecules of interest, predicted binding targets (histone deacetylase and acetyl-CoA carboxylase) were identified computationally. Overall, the inhibitor molecules characterized here showed activity against phylogenetically diverse human fungal pathogens with minimal toxic effects on human cell lines.
Related
- Plasma pre-treatment and peroxynitric acid soaking as a novel oxidative seed disinfection strategy against seed-borne fungal pathogens in maize
- Macrophages use sub-micron actin ridges in phagocytosis of encapsulated fungal pathogens
- Do fungal pathogens exploit HLA-G-mediated immune tolerance?
- Repurposing the phospholipase A2 inhibitor, darapladib, to combat multidrug-resistant fungal pathogens, including Candida auris
- Application and evaluation of nanopore targeted sequencing in the detection of bacterial and fungal pathogens in leukemia bloodstream infections.
BibTeX
@misc{spieles2026inhibitors,
title = {{Inhibitors of spore germination act against diverse human fungal pathogens}},
author = {J. A. Spieles and S. D. Greengo and A. M. Holt and M. C. Barnes and N. P. Keller and J. E. Nett and C. M. Hull},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.15.751812},
url = {https://www.biorxiv.org/content/10.64898/2026.09.15.751812v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Inhibitors of spore germination act against diverse human fungal pathogens
AU - J. A. Spieles
AU - S. D. Greengo
AU - A. M. Holt
AU - M. C. Barnes
AU - N. P. Keller
AU - J. E. Nett
AU - C. M. Hull
PY - 2026
DA - 2026/09/15
PB - bioRxiv
DO - 10.64898/2026.09.15.751812
UR - https://www.biorxiv.org/content/10.64898/2026.09.15.751812v1
AB - Current antifungal drugs often cause severe side effects due to the conservation of molecular targets between fungal and mammalian cells. One way to avoid host toxicity in future antifungals is to leverage molecules with targets involved in processes unique to fungi, such as spore germination. Germination is conserved in several of the most critical fungal pathogens but absent in mammalian cells. In this work we evaluated 191 small molecule inhibitors of Cryptococcus germination for their abilities to inhibit germination of another fungal pathogen, Aspergillus fumigatus, as well as yeast growth of Candida albicans and a pan-resistant isolate of Candida (Candidozyma) auris. The cytotoxicity of these inhibitors towards human hepatocytes and erythrocytes was also assessed. Overall, we identified 101 molecules that were either 1) germination-specific inhibitors in one or both germinating species tested, or 2) inhibitory to both germination and vegetative growth in one or more species tested. The majority of these molecules exhibited minimal toxicity to the human cell types tested. Molecules were scored and ranked for therapeutic potential based on assay data. For two key molecules of interest, predicted binding targets (histone deacetylase and acetyl-CoA carboxylase) were identified computationally. Overall, the inhibitor molecules characterized here showed activity against phylogenetically diverse human fungal pathogens with minimal toxic effects on human cell lines.
ER -